|
Pronunciation |
|
(ter
KONE a
zole) |
|
|
U.S. Brand
Names |
|
Terazol®
Vaginal |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Triaconazole |
|
|
Pharmacological Index |
|
Antifungal Agent, Vaginal |
|
|
Use |
|
Local treatment of vulvovaginal candidiasis |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Known hypersensitivity to terconazole or components of the vaginal cream or
suppository |
|
|
Warnings/Precautions |
|
Should be discontinued if sensitization or irritation occurs. Microbiological
studies (KOH smear and/or cultures) should be repeated in patients not
responding to terconazole in order to confirm the diagnosis and rule out other
other pathogens. |
|
|
Adverse
Reactions |
|
1% to 10%: Genitourinary: Vulvar/vaginal burning |
|
|
Drug
Interactions |
|
No data reported |
|
|
Stability |
|
Room temperature (13°C to
30°C/59°F to
86°F) |
|
|
Mechanism of
Action |
|
Triazole ketal antifungal agent; involves inhibition of fungal cytochrome
P-450. Specifically, terconazole inhibits cytochrome P-450-dependent
14-alpha-demethylase which results in accumulation of membrane disturbing
14-alpha-demethylsterols and ergosterol depletion. |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Extent of systemic absorption after vaginal administration may be
dependent on the presence of a uterus; 5% to 8% in women who had a hysterectomy
versus 12% to 16% in nonhysterectomy women |
|
|
Usual Dosage |
|
Adults: Female: Insert 1 applicatorful intravaginally at bedtime for 7
consecutive days |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Complete full course of therapy as directed. Insert vaginally as directed by
prescriber or see package insert. Sexual partner may experience irritation of
penis; best to refrain from intercourse during period of treatment. Report
persistent vaginal burning, itching, irritation, or discharge.
Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend
to be pregnant. Consult prescriber if breast-feeding. |
|
|
Nursing
Implications |
|
Watch for local irritation; assist patient in administration, if necessary;
assess patient's ability to self-administer, may be difficult in patients with
arthritis or limited range of motion |
|
|
Dosage Forms |
|
Cream, vaginal: 0.4% (45 g); 0.8% (20 g)
Suppository, vaginal: 80 mg (3s) |
|
|
References |
|
Drug Facts and Comparisons, St Louis, MO: 1989, 528-9.
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|